Effects of dalcetrapib in patients with a recent acute coronary syndrome

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Observational studies link higher high-density lipoprotein (HDL) cholesterol to reduced coronary heart disease (CHD) risk.
• Therapeutic elevation of HDL cholesterol's impact on cardiovascular risk is not well-established.
• Cholesteryl ester transfer protein (CETP) inhibitors raise HDL cholesterol, potentially improving cardiovascular outcomes.

Purpose of the Study:

• To evaluate the efficacy of the CETP inhibitor dalcetrapib in reducing cardiovascular events in patients with recent acute coronary syndrome.
• To determine if increasing HDL cholesterol levels through dalcetrapib therapy translates to improved cardiovascular outcomes.

Main Methods:

• A randomized trial involving 15,871 patients post-acute coronary syndrome.
• Participants received either dalcetrapib (600 mg daily) or placebo, alongside standard evidence-based care.
• The primary endpoint was a composite of CHD death, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation.

Main Results:

• Dalcetrapib significantly increased HDL cholesterol levels (31-40%) compared to placebo (4-11%).
• No significant reduction in the primary composite endpoint was observed (HR, 1.04; 95% CI, 0.93-1.16; P=0.52).
• Dalcetrapib did not affect LDL cholesterol levels, total mortality, or individual components of the primary endpoint, but slightly increased C-reactive protein and systolic blood pressure.

Conclusions:

• Dalcetrapib effectively raised HDL cholesterol levels in patients with recent acute coronary syndrome.
• The trial was terminated for futility as dalcetrapib did not reduce the risk of recurrent cardiovascular events.
• These findings suggest that raising HDL cholesterol via CETP inhibition may not be a viable strategy for cardiovascular risk reduction in this patient population.